Cellectar Biosciences Inc股票

CELLECTAR BIOSCIENCES INC C/WTS 20/04/2021(TO PUR COM ... 雪球为您提供cellectar biosciences inc c/wts 20/04/2021(to pur com)(clrbz)股票实时行情,资金流向,新闻资讯,研究报告,社区互动,交易信息,个股点评,公告,财务指标分析等与cellectar biosciences inc c/wts 20/04/2021(to pur com)(clrbz)股票相关的信息与服务. Cellectar Biosciences, Inc. Common Stock (CLRB) Press ... CLRB Cellectar Biosciences, Inc. Common Stock. Data is currently not available. $1.36. 0.05 Cellectar Biosciences to Host a CLR 131 Clinical Data Call with Its Phase 2 Lead Investigator on

On Oct. 12, Cellectar Biosciences Inc. (NASDAQ:CLRB) raised $7.8 million through the sale of shares and convertible stock in a registered direct offering. Cellectar sold 2 million common shares at $1.87 and 41 preferred shares

Cellectar Biosciences Announces Pricing of $20 Million Underwritten Public Offering. Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the pricing of an underwritten public offering for gross proceeds of $20.0 million, prior to deducting underwriting Real-time exchange rate quote of Cellectar Biosciences, Inc. including detailed information, live chart and news, profile and other market data. Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of drugs for the treatment of cancer. 查看实时cellectar biosciences inc图表以跟踪其股票的价格行为。查找市场预测，clrb财务指标和市场新闻。

CLRB stock forecast Our latest prediction for Cellectar BioSciences, Inc.'s stock price was made on the Nov. 30, 2018 when the stock price was at 2.23$.. In the short term (2weeks), CLRB's stock price should outperform the market by 5.21%.During that period the price should oscillate between -9.99% and +17.34%.. In the medium term (3months), CLRB's stock price should outperform the market by 8

郑重声明：本网站所刊载的所有资料及图表仅供参考使用。投资者依据本网站提供的信息、资料及图表进行金融、证券等投资 Company Name: Cellectar Biosciences Inc., Stock Symbol: CLRB, Industry: Biotechs, Total Posts: 7980, Last Post: 5/26/2020 3:38:35 PM On Oct. 12, Cellectar Biosciences Inc. (NASDAQ:CLRB) raised $7.8 million through the sale of shares and convertible stock in a registered direct offering. Cellectar sold 2 million common shares at $1.87 and 41 preferred shares CLRB Description — Cellectar Biosciences Inc. Cellectar Biosciences is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Cellectar Biosciences Announces CLR 131 Achieves Primary Efficacy Endpoints from Its Phase 2 CLOVER-1 Study in Relapsed/Refractory B-cell Lymphomas and Completion of the Phase 1 Relapsed/Refractory Multiple Myeloma Dose Escalation Study. Stock Information for Cellectar Biosciences Inc.

Cellectar Biosciences Inc - CLRB Stock Chart Technical Analysis for 09-08-16 Free Guide - The 5 Tools I Use To Find Stocks To Trade: https:

美股上市股票Cellectar Biosciences, Inc. Series A Warrants,在NASDAQ交易所挂牌上市，中文名称Cellectar Biosciences, Inc. Series A Warrants,股票代码。客服热线：010-84185831 扫码关注微信 Cellectar Biosciences to Host a CLR 131 Clinical Data Call with Its Phase 2 Lead Investigator on February 19, 2020 (01-07 20:00) Cellectar Appoints Dr. Igor Grachev as Chief Medical Officer Cellectar Biosciences Inc is a clinical stage biopharmaceutical company. It focusses on development of targeted phospholipid drug conjugates for the treatment and imaging of cancer. The company's pipeline consists of pre-clinical and clinical product candidates including radiotherapeutic and chemotherapeutic phospholipid drug conjugates. Real time Cellectar Biosciences, Inc. (CLRB) stock price quote, stock graph, news & analysis.

Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micro metastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer

Cellectar Biosciences, Inc. 100 Campus Drive, Suite 207 Florham Park, NJ 07932 Cellectar Biosciences Inc(CLRB)股票价格_行情_走势图—东方财富网提供Cellectar Biosciences Inc(CLRB)股票的行情走势、五档盘口、逐笔交易等实时行情数据，及Cellectar Biosciences Inc(CLRB)的资讯、公司公告、研究报告、行业研报、F10资料、行业资讯、资金流分析、阶段涨幅、所属板块、财务指标、机构观点、行业排名、估值水平、股吧互动等与Cellectar Biosciences Inc(CLRB)有关的